Cellective BioTherapy, Inc. (CBT) is a biotechnology company founded in 2015 that is developing antibody and cell-based approaches to harnessing regulatory B (B10) cells for both augmenting a patient's immunity against tumors and for the production of personalized cellular therapies to treat diverse and complex inflammatory disorders and autoimmune disease. Our proprietary immunotherapy pipeline and technology focus on unique aspects of B cell biology that are involved in regulating a variety of autoimmune diseases and inflammatory immune responses.
We are developing two regulatory B10 cell-based platform technologies that can either enhance or inhibit immune responses.
We are advancing monoclonal antibodies that deplete regulatory B10 cells without destroying other essential B cells to enhance a patient's immune response to cancer and complement current immunotherapies, accelerate immune responses to infection, and act as an adjuvant for vaccines.
Our technology also has the unprecedented ability to expand human regulatory B10 cells ex vivo for use as an autologous (patient-sourced) cellular immunotherapy for autoimmune disease, chronic graft versus host disease (cGVHD), and transplantation, as well as the treatment of immunodeficiency.
Targeted Immune Activation
Monoclonal Antibody-Induced B10 Cell Depletion
Targeted Disease Suppression
B10 Cell Expansion
Our B10 cell-directed therapies are unique in their approach, solve unmet clinical needs, and distinguish us from others working in the immunotherapy space. While the importance of B10 cells has been demonstrated in mouse models of inflammation, autoimmunity, solid tumors and infection, they may have additional future applications for the treatment of human disease where effective therapies do not exist.
Cellective‘s technologies and a comprehensive IP portfolio were licensed exclusively from Duke University, including recently issued patents within the field. We have also developed additional novel technology platforms based on these assets, which provide a broad base for future expansion.